Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial aims to tame overactive immune system in lupus patients

NCT ID NCT07371468

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults expected to join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy myositis disease rheumatoid arthritis Sjogren syndrome systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, 1181, Argentina

  • GSK Investigational Site

    RECRUITING

    San Miguel de Tucumán, T4000IHE, Argentina

  • GSK Investigational Site

    RECRUITING

    Campinas, São Paulo, Brazil

  • GSK Investigational Site

    RECRUITING

    São Paulo, São Paulo, 01232-010, Brazil

  • GSK Investigational Site

    RECRUITING

    Bordeaux, 33000, France

  • GSK Investigational Site

    RECRUITING

    Toulouse, 31059, France

  • GSK Investigational Site

    RECRUITING

    Cona, Ferrara, Italy

  • GSK Investigational Site

    RECRUITING

    Fukuoka, 812-8582, Japan

  • GSK Investigational Site

    RECRUITING

    Hiroshima, 734-8551, Japan

  • GSK Investigational Site

    RECRUITING

    Hokkaido, 060-8648, Japan

  • GSK Investigational Site

    RECRUITING

    Panama City, Panama

  • GSK Investigational Site

    RECRUITING

    Panama City, Panama

  • GSK Investigational Site

    RECRUITING

    Panama City, Panama

  • GSK Investigational Site

    RECRUITING

    Poznan, 61-848, Poland

  • GSK Investigational Site

    RECRUITING

    Warsaw, 02-637, Poland

  • GSK Investigational Site

    RECRUITING

    Barcelona, 08025, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28040, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28046, Spain

  • GSK Investigational Site

    RECRUITING

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.